Verve Therapeutics Announces Interim Data For VERVE-101 Demonstrating First Human Proof-Of-Concept For In Vivo Base Editing With Dose-Dependent Reductions In LDL-C And Blood PCSK9 Protein In Patients With Heterozygous Familial Hypercholesterolemia

Press/Media

Period13 Nov 2023

Media coverage

1

Media coverage

  • TitleVerve Therapeutics Announces Interim Data For VERVE-101 Demonstrating First Human Proof-Of-Concept For In Vivo Base Editing With Dose-Dependent Reductions In LDL-C And Blood PCSK9 Protein In Patients With Heterozygous Familial Hypercholesterolemia
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date13/11/23
    PersonsValentin Fuster
View all 1
View less